Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

"Comparison of Spirulina Gels for Treating Stage II Grade B Periodontitis"

NCT06699654 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-10-21
Last updated
2025-02-11

Condition(s) studied

Periodontitis Stage II

Investigational drug(s) / intervention(s)

Placebo gelSpirulina GelSpirulina Nanoparticles Gel

Placebo gel: A gel without active Spirulina components applied as a control intervention.

Spirulina Gel: A conventional Spirulina gel formulation applied as a periodontal therapy.

Spirulina Nanoparticles Gel: A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.

Study summary

This randomized controlled clinical study investigates the effectiveness of Spirulina gel and Spirulina nanoparticles gel in treating Stage II Grade B periodontitis. The research aims to compare the two formulations in terms of clinical, radiological, and biochemical outcomes, such as pocket depth reduction, alveolar bone density improvement, and inflammatory marker levels. The study seeks to provide insights into the potential of Spirulina-based therapies for enhancing periodontal health.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion criteria: * Patients with good systemic health. * Patients who can maintain good oral hygiene. * Attachment loss 3-4 mm and probing pocket depth ≤ 5mm. Exclusion criteria for this study include: · * Any systemic disease that affects the periodontium. · * Pregnant, postmenopausal women. · * People who take anti-inflammatory drugs, antibiotics, or vitamins within the previous 3 month. * People who use mouth washes regularly · * Participation in other clinical trials.

Primary outcome measure(s)

  • Reduction in Probing Pocket Depth (PPD) — at baseline, 1 month , 3 months, 6 months
    The mean reduction in probing pocket depth in millimeters (mm) at periodontal sites treated with Spirulina gel and Spirulina nanoparticles gel.

Trial sites (1)

FacilityCityRegionStatus
Doctor Mohamed Samir Periodontal and Implantology Clinic El-Sheikh Zayed City Cairo Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06699654 on ClinicalTrials.gov ↗ ← All trials in Egypt